Free tool
Drug Trial Radar: Oncology
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
2,031
Recruiting, industry sponsors, Oncology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting2,031
- Completed5,416
2,031 trials
Showing 1 to 25, recently updated first.
Arvinas Inc.Industry
NCT06393738 · 329 participants (planned) · Start Sep 5, 2024 · Primary completion Dec 2028
Drug: ARV-393; Glofitamab · For: Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Sites: New Haven, Connecticut; Miami, Florida; Detroit, Michigan · 28 sites in all
PfizerPfizer (PFE)
NCT07227298 · 162 participants (planned) · Start Jan 30, 2026 · Primary completion Mar 8, 2029
Drug: PF-08634404; Sigvotatug Vedotin and 1 more · For: Advanced/Metastatic Non-Small Cell Lung Cancer; Carcinoma, Non-Small Cell Lung; Non-Small Cell Lung Cancer
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 108 sites in all
PhotonPharma, Inc.Industry
NCT06366490 · 12 participants (planned) · Start Feb 12, 2026 · Primary completion Nov 2028
Drug: Innocell · For: Ovarian Cancer (OvCa)
Sites: Duarte, California
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Recruiting
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
NCT07140016 · 40 participants (planned) · Start Sep 22, 2025 · Primary completion Dec 31, 2029
Drug: gilteritinib · For: Non-small Cell Lung Cancer (NSCLC); Anaplastic Lymphoma Kinase (ALK) Positive
Sites: Fullerton, California; Orange, California; Edwards, Colorado · 17 sites in all
PfizerPfizer (PFE)
NCT07227012 · 138 participants (planned) · Start Dec 1, 2025 · Primary completion Oct 18, 2027
Drug: PF-08634404; Ipilimumab · For: Carcinoma, Hepatocellular; Hepatocellular Cancer; Hepatocellular Carcinoma and 4 more
Sites: Phoenix, Arizona; Irvine, California; Los Angeles, California · 81 sites in all
Molecular Partners AGIndustry
NCT07278479 · 138 participants (planned) · Start May 18, 2026 · Primary completion Sep 2028
Drug: [212Pb]Pb-MP0712 · For: Large Cell Neuroendocrine Carcinoma; Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) and 4 more
Sites: Miami, Florida; Tampa, Florida; Atlanta, Georgia · 9 sites in all
Adcendo ApSIndustry
NCT06797999 · 270 participants (planned) · Start Jun 5, 2025 · Primary completion Feb 27, 2029
Drug: Antibody-drug conjugate (ADC) · For: Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
Sites: Aurora, Colorado; Miami, Florida; New York, New York · 9 sites in all
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT07591155 · 22 participants (planned) · Start May 13, 2026 · Primary completion Dec 2027
Drug: BL-ARC002 · For: Lung Cancer; Breast Cancer; Head and Neck Squamous Cell Carcinoma and 1 more
Sites: Tianjin, China
Allterum Therapeutics, IncIndustry
NCT07586618 · 24 participants (planned) · Start Jun 1, 2026 · Primary completion May 2028
Drug: 4A10 · For: Lymphoblastic Lymphoma; Acute Lymphoblastic Leukemia ALL
Sites: Aurora, Colorado; Chicago, Illinois; Indianapolis, Indiana · 9 sites in all
Whitehawk Therapeutics, Inc.Industry
NCT07444814 · 226 participants (planned) · Start Dec 19, 2025 · Primary completion Sep 2028
Drug: HWK-007 · For: Endometrial Cancer; Ovarian Cancer; Ovarian Cancer Metastatic and 4 more
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 17 sites in all
IDEAYA BiosciencesIndustry
NCT07277413 · 570 participants (planned) · Start Mar 4, 2026 · Primary completion Apr 30, 2028
Drug: IDE892; IDE397 and 1 more · For: Bladder Cancer; Mesothelioma; Pleural Mesothelioma and 5 more
Sites: Goodyear, Arizona; Phoenix, Arizona; Duarte, California · 26 sites in all
- SLV-154 Treatment of Advanced CancersRecruiting
Solve TherapeuticsIndustry
NCT06771219 · 250 participants (planned) · Start May 14, 2025 · Primary completion Aug 2027
Drug: SLV-154 · For: Advanced Cancer; Advanced Solid Tumor; Metastatic Cancer
Sites: Beverly Hills, California; Newport Beach, California; Santa Monica, California · 14 sites in all
PfizerPfizer (PFE)
NCT07421700 · 132 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 28, 2027
Drug: PF-08634404; Enfortumab Vedotin · For: Urothelial Cancer; Advanced/Metastatic Urothelial Cancer; Urothelial Carcinoma
Sites: Fayetteville, Arkansas; Rogers, Arkansas; Springdale, Arkansas · 198 sites in all
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsPivotal-lookingRecruiting
Olema Oncology, Inc.Industry
NCT06784193 · 180 participants (planned) · Start Dec 16, 2024 · Primary completion May 30, 2027
Drug: OP-3136; Fulvestrant and 1 more · For: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC); Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC) and 3 more
Sites: Gilbert, Arizona; Aurora, Colorado; Sarasota, Florida · 25 sites in all
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT07100106 · 285 participants (planned) · Start Oct 7, 2025 · Primary completion Aug 31, 2028
Drug: GDC-4198; Giredestrant and 1 more · For: Breast Cancer
Sites: Huntsville, Alabama; Tucson, Arizona; Duarte, California · 77 sites in all
Regor Pharmaceuticals Inc.Industry
NCT07524322 · 63 participants (planned) · Start Jul 21, 2026 · Primary completion Apr 2028
Drug: RGT-490 · For: Breast Cancer; Ovarian Cancer; Endometrial Cancer and 6 more
Sites: Los Angeles, California; Boston, Massachusetts; Pittsburgh, Pennsylvania · 7 sites in all
Voronoi, IncIndustry
NCT07699328 · 315 participants (planned) · Start Mar 26, 2024 · Primary completion Jan 1, 2029
Drug: VRN110755 · For: EGFR-Mutant Non-Small Cell Lung Cancer
Sites: Bedford Park, Australia; Clayton, Australia; Toronto, Canada · 29 sites in all
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07227415 · 224 participants (planned) · Start Feb 10, 2026 · Primary completion Nov 2, 2027
Drug: PF-08634404; Ipilimumab and 2 more · For: Carcinoma, Renal Cell; Advanced Renal Cell Carcinoma; Renal Cancer and 10 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fayetteville, Arkansas · 186 sites in all
Genovn Therapeutics (Suzhou) Co., Ltd.Industry
NCT07621471 · 12 participants (planned) · Start Nov 18, 2026 · Primary completion Dec 31, 2028
Drug: IL-15 enhanced engineered NK cells; IL-15 Enhanced Engineered NK Cells · For: Solid Tumors; Metastatic Cancer
Sites: Chongqing, China
Tethra Biosciences Inc.Industry
NCT05358379 · 330 participants (planned) · Start Apr 14, 2022 · Primary completion Nov 2028
Drug: THT140 · For: Solid Tumor, Adult Lymphoma
Sites: New York, New York; Houston, Texas; Seattle, Washington · 5 sites in all
- A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.Recruiting
Outpace Bio, Inc.Industry
NCT07664735 · 30 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 2030
Drug: OPB-201 · For: Endometrial Cancer Recurrent; Endometrial Cancer; Advanced Endometrial Cancer and 4 more
Sites: San Francisco, California; Atlanta, Georgia; Detroit, Michigan · 5 sites in all
Cellogen Therapeutics Pvt. Ltd.Industry
NCT07948733 · 18 participants (planned) · Start Oct 26, 2026 · Primary completion Sep 14, 2028
Drug: Autologous bispecific CD20/CD19 CAR-T cells - 1 × 10⁶ cells/kg; Autologous bispecific CD20/CD19 CAR-T cells - 2 × 10⁶ cells/kg and 1 more · For: B-Cell Non-Hodgkin Lymphoma (NHL); B-cell Acute Lymphoblastic Leukemia (B-ALL)
Sites: Vellore, India
Hansoh BioMedical R&D CompanyIndustry
NCT06892379 · 631 participants (planned) · Start Feb 26, 2025 · Primary completion Dec 31, 2026
Drug: HS-20110; HS-20110 and 2 more · For: Solid Tumors
Sites: Tamarac, Florida; Atlanta, Georgia; Fort Wayne, Indiana · 9 sites in all
Wuhan KadGeno Biotechnology Co., LtdIndustry
NCT07948083 · 304 participants (planned) · Start Jan 6, 2026 · Primary completion Nov 30, 2027
Drug: KDTV001 · For: HPV (Human Papillomavirus)-Associated; HPV 16/18; HPV 52 and 1 more
Sites: Wuhan, China · 2 sites in all
Stemline Therapeutics, Inc.Industry
NCT05386108 · 73 participants (planned) · Start Aug 31, 2022 · Primary completion Aug 2027
Drug: Elacestrant; Abemaciclib · For: Breast Neoplasms; Brain Neoplasms; Neoplasms by Site and 5 more
Sites: Fullerton, California; Los Angeles, California; Urbana, Illinois · 86 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.